Recently Featured

Revolution Drug Shows Promise in Early Pancreatic Cancer

May 7, 2026
Recent findings indicate that Revolution’s therapy may significantly alter the treatment landscape for early-stage pancreatic cancer, a malignancy known for its challenging prognosis and limited therapeutic options. This innovative approach builds on previous data suggesting that the drug could not only improve patient outcomes but also generate substantial revenue, potentially reaching billions in sales. The…

Monitoring Mammalian and Microbial Bioprocesses in Real Time

May 7, 2026
At the 2026 BiOS conference in San Francisco, researchers presented a biosensing platform known as TissueSense, which aims to enhance the monitoring of living cells and tissues during drug bioprocessing. This innovative system offers continuous, real-time insights into cellular behavior without disrupting the biological environment, addressing a critical need in biopharmaceutical manufacturing. Maintaining consistent cell…

Overcoming the VLP Purification Bottleneck

May 7, 2026
Virus-like particles (VLPs) are gaining traction among biomanufacturers due to their favorable biosafety profiles and immunogenicity, yet the downstream purification process remains a significant bottleneck. According to a recent review by Jingchao Zhang, PhD, and Chen Chen, successful VLP purification demands an integrated, product-specific process design that aligns with the critical quality attributes of the…

Immunotherapy in Locally Advanced HNSCC: Is There Still Room for New Agents?

May 7, 2026
The treatment landscape for locally advanced head and neck squamous cell carcinoma (LA HNSCC) has evolved dramatically in recent years, driven by advancements in immunotherapy. Agents such as pembrolizumab and nivolumab have become staples in treatment regimens, demonstrating significant efficacy and reshaping patient outcomes. However, the question remains: is there still room for new agents…

Ongoing Cases